Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01895985 · ClinicalTrials.gov registry record · Phase 1
Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers
A Phase 1 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01895985 is a Phase 1 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 24 participants.
The verdict
NCT01895985, a Phase 1 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effect of latanoprostene bunod dosed once daily (QD) in reducing intraocular pressure (IOP) measured over a 24-hour period in healthy subjects.
Interventions
- DRUG Latanoprostene bunod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01895985
The ClinicalTrials.gov registry entry for NCT01895985 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Latanoprostene bunod is the first listed.
NCT01895985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01895985 about?
NCT01895985 is a clinical study titled "Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers". The objective of this study is to evaluate the effect of latanoprostene bunod dosed once daily (QD) in reducing intraocular pressure (IOP) measured over a 24-hour period in healthy subjects.
What is the current status of trial NCT01895985?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-07. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01895985?
The interventions under investigation include: Latanoprostene bunod (DRUG).
Who is sponsoring clinical trial NCT01895985?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.